Bristol-Myers Squibb Company Stock (US0897961004): Quarter in focus after reported revenue of $11.49 billion

Bristol-Myers Squibb is in focus on Tuesday after its latest reported quarter showed revenue of $11.49 billion, according to Ad Hoc News. The stock is also being tracked against its U.S. listing and current valuation backdrop.

By AD HOC NEWS - Companies & Analysis Desk Team | June 16, 2026

Bristol-Myers Squibb Company stock is in focus on Tuesday after the latest reported quarter showed revenue of $11.49 billion, according to Ad Hoc News. That figure is the main fresh trigger available in the current news flow, and it puts the drugmaker back under the microscope for investors watching earnings momentum and execution.

Quarterly revenue is the key fresh data point

Ad Hoc News reported that Bristol Myers Squibb posted $11.49 billion in revenue in its most recently reported quarter, alongside the context that the result was being measured against analyst expectations. The same report frames the stock around quarterly numbers rather than a new deal, a guidance reset, or a major legal headline, which keeps the earnings lens at center stage.

The company remains a large-cap U.S. healthcare name and one of the more closely followed pharmaceutical stocks in the market. Its listing, ticker, and identifier matter for readers following the shares across U.S. and global screens: Bristol-Myers Squibb trades on the New York Stock Exchange under BMY and carries ISIN US0897961004.

For context, the company also maintains an investor relations hub on its own website, which is the appropriate place to track official updates, filings, and corporate communications. That matters because quarterly revenue headlines often move the conversation faster than the company can add color through a formal earnings package or presentation.

The stock is not trading in a vacuum. Bristol-Myers Squibb is a healthcare and pharmaceutical company with revenue tied to prescription drugs and other life science products, so investors usually read each quarter through product sales, pipeline updates, and margin trends rather than through short-term market sentiment alone.

There is also a second market reference point available today: an Xetra order book page shows a quoted price of 49.470 euros, which gives a cross-market snapshot for the name outside the U.S. session. Because that quote comes from a separate venue, it should be treated as a reference point rather than a U.S. closing price.

At the same time, the available news set does not show a new analyst rating change, a fresh price target, or an updated management outlook in the materials reviewed for this article. That keeps the story tightly anchored to the quarterly revenue print and the market's reaction framework around it.

Key facts on Bristol-Myers Squibb stock

• Name: Bristol-Myers Squibb Company
• Industry: Pharmaceuticals, healthcare
• Headquarters: New York, New York, United States
• Core markets: Prescription medicines and global healthcare markets
• Revenue drivers: Branded prescription drugs, commercial portfolio execution, and pipeline progress
• Listing: New York Stock Exchange, ticker BMY
• Trading currency: U.S. dollars

More Bristol-Myers Squibb news at a glance

The current story flow is centered on the company name and its quarterly results, so the most relevant follow-up is whether the next company update confirms the revenue trend or changes the tone on outlook. Investors who want to monitor the next headlines can follow the company and market coverage through Ad Hoc News and Bristol Myers Squibb's own investor relations materials.

For now, the stock is best described as a quarterly-results name in focus, not a headline driven by a large same-day swing or a fresh strategic announcement. That distinction matters because it keeps the interpretation grounded in the most verifiable new fact available: reported quarterly revenue of $11.49 billion.

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.